ArticleBMC pregnancy and childbirth2026
Association of late-pregnancy triglyceride-glucose index and growth differentiation factor 15 with adverse pregnancy outcomes in women with gestational diabetes mellitus.
Article in BMC pregnancy and childbirth, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundGestational diabetes mellitus (GDM) is a common metabolic disorder during pregnancy and is closely associated with adverse pregnancy outcomes (APO), such as preeclampsia, preterm birth, and macrosomia. The triglyceride-glucose (TyG) index and growth differentiation factor 15 (GDF-15) have emerged as novel biomarkers in cardiovascular and metabolic diseases. However, their potential relevance to APO in late pregnancy among women with GDM remains unclear.
methodsA total of 275 pregnant women diagnosed with GDM between January 2024 and March 2025 were enrolled in this study. Participants were categorized into two groups based on the presence or absence of APO: GDM patients with APO and GDM patients without APO. Serum levels of GDF-15 were measured using enzyme-linked immunosorbent assay (ELISA), and the TyG index was calculated using fasting triglyceride and glucose levels.
resultsCompared with the GDM without APO group, patients in the GDM with APO group exhibited significantly higher serum levels of GDF-15 and TyG index (both p < 0.05). Multivariate logistic regression analysis revealed that both the TyG index (OR = 1.672, 95%CI:1.074–2.602, p < 0.05) and GDF-15 (OR = 1.002, 95%CI:1.001–1.003, p < 0.05) were independent predictors of APO. After adjusting for all potential confounders, restricted cubic spline analysis indicated a positive association between both biomarkers and the risk of APO. Furthermore, receiver operating characteristic (ROC) analysis demonstrated that the combined model incorporating TyG and GDF-15 yielded an AUC of 0.722 (95%CI:0.661–0.784), suggesting good predictive performance.
conclusionElevated TyG index and GDF-15 levels in late pregnancy are potential predictive biomarkers for APO in women with GDM. Combined assessment of these markers may enhance clinical risk stratification and inform targeted management strategies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.